Advertisement
Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

MRI Featured content

June 23, 2011 4:37 am | by Diagnostic Imaging | News | Comments

MRI Featured content

NewCardio Board of Directors Elects Patrick Maguire Chairman

June 23, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., June 23, 2011 /- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that Patrick Maguire , MD, PhD, member of the NewCardio board of directors since March of 2008 and a proven leader and a seasoned executive with experience in a...

Radient Pharmaceuticals Corporation Joins OTCQX

June 23, 2011 2:40 am | by Bio-Medicine.Org | News | Comments

NEW YORK, June 23, 2011 /- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Radient Pharmaceuticals Corporation (OTCQX: RXPC), the developer and worldwide marketer...

Advertisement

O2h to Provide Chemistry Support to Chromocell

June 23, 2011 12:38 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, England, AHMEDABAD, India and NORTH BRUNSWICK, New Jersey, June 23, 2011 /-   Oxygen Healthcare Ltd. (O2h), a Piramal Group Company and Chromocell Corporation , an emerging life sciences company active in both flavors and therapeutics discovery, today signed an agreement...

Ekahau Embeds RTLS in Nordic ID RFID Readers to Add Location Tracking to Passive RFID Tags and Barcode

June 23, 2011 12:38 am | by Bio-Medicine.Org | News | Comments

RESTON, Virginia, June 23, 2011 /-   Ekahau, the worldwide leader in high performance Wi-Fi-based Real Time Location Systems (RTLS) , today announced that, in conjunction with Nordic ID, it has developed a solution for adding location information to passive RFID and barcode labels....

Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery

June 23, 2011 12:37 am | by Bio-Medicine.Org | News | Comments

BANGALORE, India, June 23, 2011 /-   Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area. The collaboration, initiated two years ago in...

A First Step Toward a Prosthesis for Memory

June 22, 2011 8:40 pm | by Massachusetts Institute of Technology | News | Comments

A neural implant helps rats with short-term recall.

MiMedx Group Receives FDA Clearance to Market Its HydroFixâ„¢ Ortho Shieldâ„¢ Device

June 22, 2011 12:39 pm | by Bio-Medicine.Org | News | Comments

MARIETTA, Ga., June 22, 2011 /- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials including bioimplants processed from human amniotic membrane, announced today that the Company's proprietary device,...

Advertisement

Getting a Reed on Miniaturizing Magnetic Switches

June 22, 2011 12:34 pm | by Paul Linsley | Articles | Comments

The reduction in size of medical electronics is a benefit of component suppliers across the board making their products smaller with lower power requirements. This article looks at the benefits achieved from the miniaturization of magnetic reed switches and the specific applications in which they are used. 

Ceramic Replaces Titanium With Machining Assistance

June 22, 2011 9:55 am | by Klaus A. Burckhardt, PE | Articles | Comments

Coated titanium was to be replaced as the material for the stator housing in a right ventrical assist device. Zirconia ceramic was the material selected and expert machining met the needs for very tight tolerances to fabricate the component.

National Association of Public Hospitals and Health Systems to Galvanize Member Relationships on Within3

June 22, 2011 9:45 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, June 22, 2011 /- The National Association of Public Hospitals and Health Systems (NAPH) announced plans to launch an exclusive online community for employees at its member hospitals, becoming one of the first hospital associations to expand into a year-round Within3 online...

Uterine Fibroid Patient Featured on CBS Evening News Has Become an Advocate for MR-Guided Focused Ultrasound

June 22, 2011 9:45 am | by Bio-Medicine.Org | News | Comments

CHARLOTTESVILLE, Va., June 22, 2011 /- On June 12, 2011, viewers of the CBS Evening News learned about Stephanie Small's gripping story. Suffering from a large uterine fibroid, the 27-year-old was treated last December as part of a MR-guided focused ultrasound clinical trial at the...

Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)

June 22, 2011 9:45 am | by Bio-Medicine.Org | News | Comments

In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study.  The propriety formulation was designed and manufactured at Particle... 

Advertisement

Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma

June 22, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

VIENNA, June 22, 2011 /-   Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children ' s Cancer Research...

Asmacure Ltee to Present at the 2011 BIO Business Forum During the Annual BIO International Convention

June 22, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

QUEBEC CITY, June 22, 2011 /- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will be presenting at the 2011 BIO...

"SMART" Health App Competition Concludes, Names $5,000 Winner

June 22, 2011 7:38 am | by Bio-Medicine.Org | News | Comments

BOSTON, June 22, 2011 /PRNewswire-USNewswire/ --   Corporations, academics and private citizens responded to a national developer challenge issued this spring by researchers at Children's Hospital Boston and Harvard Medical School designed to inspire innovation in health information...

Lupin Announces Launch of Generic Levaquin® Tablets

June 22, 2011 7:37 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, June 22, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil's Levaquin®...

Mr. Ronald L. Chez Filed Amended 13D for RepliGen Corporation

June 22, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, June 22, 2011 /- Amended 13D for RepliGen Corporation was filed with the SEC by Mr. Ronald L. Chez, a private investor. Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor. RepliGen Corporation is a biopharmaceutical company focused on building an...

New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes

June 22, 2011 6:45 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., June 22, 2011 /- Allergan, Inc. (NYSE: AGN ) today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND® Adjustable...

The SCOOTER Store Expands Insurance Health Plan Relationships

June 22, 2011 6:44 am | by Bio-Medicine.Org | News | Comments

NEW BRAUNFELS, Texas, June 22, 2011 /- The SCOOTER Store, the nation's leading provider of power mobility solutions, announced that its business agreements with insurance companies have exceeded 200 health plan partnerships.  The contracts allow more than 170 million covered members...

CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary

June 22, 2011 6:42 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, June 22, 2011 /- CardioGenics Holdings Inc. (CGNH.OB) announced today the transfer of its magnetic beads business unit, which develops ultra sensitive magnetic beads for use in diagnostic devices, into its Canadian subsidiary, Luxspheres Inc. The beads business unit,...

Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation

June 22, 2011 6:42 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 22, 2011 /- Cardium Therapeutics (NYSE Amex: CXM ) today announced the selection of the Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory (Cedars-Sinai Core Laboratory), Los Angeles, California, to serve as the central core lab for the Company’s Generx...

Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics for Alzheimer's Disease

June 22, 2011 6:41 am | by Bio-Medicine.Org | News | Comments

NEW YORK , June 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation. (Logo:...

ProStrakan Receives FDA Approval for Rectivâ„¢ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures

June 22, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

GALASHIELS, Scotland, and BEDMINSTER, N.J., June 22, 2011 /- ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for...

Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

June 22, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

EVANSTON, Ill., June 22, 2011 /- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.  GLYX-13, a Glycine-site...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading